06 February 2013 | News | By BioSpectrum Bureau
Hope for cardiac patients - Allied Healthcare and CSIRO study reveal that CardioCel tissue patches have superior ability to maintain stems cells in heart surgery
Singapore: Australia's Allied Healthcare's CardioCel tissue patches has shown superiority for stem cells survival and growth as compared to the gold-standard tissues in surgical use.
Jointly done with the Commonwealth Scientific and Industrial Research Organization (CSIRO), the study compared the performance of CardioCel engineered tissue against glutaraldehyde-prepared tissue, which is widely used in cardiac repair surgery, and assessed their ability to maintain a viable population of mesenchymal stems cells (MSCs).
"These data further supports our recent announcement on tissue regeneration that CardioCel implants offer in reconstructing heart valves and broadens the potential of Aadapt-prepared tissue to be used as scaffolds to seed and deliver stem cells for soft tissue repair," said Mr Lee Rodne, Allied Healthcare's MD.
"This is exciting as it expands the potential of our Adapt tissue to be used as a truly regenerative treatment for a number of diseases and conditions. The first product CardioCel will be launched into the global market within the next 12 months," he added.
The study demonstrated positive results supporting the potential for Allied's Adapt tissue treatment technology across a range of surgical applications, with the opportunity to have a significant impact on many global markets for soft tissue repair. In addition to the initial cardiovascular suite of products, such as CardioCel, Allied Healthcare Group is evaluating how the Adapt platform can be used in pelvic floor reconstructions, hernia repairs and orthopaedics, as well as a biological scaffold to grow and deliver stem cells.